This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jansen, G. Articles by Schornagel, J. H. Search for Related Content PubMed PubMed Citation Articles by Jansen, G. Articles by Schornagel, J. H.

Identification of a Membrane-associated Folate-binding Protein in Human Leukemic CCRF-CEM Cells with Transport-related Methotrexate Resistance¹

Oncology Unit, Department of Internal Medicine [G. J., G. R. W., I. K., B. C. R., J. H. S.], and Laboratory of Medical Enzymology, Department of Haematology [G. R.], University Hospital Utrecht, The Netherlands

CEM/MTX cells, a subline of CCRF-CEM cells resistant to methotrexate (MTX) by virtue of impaired transport by the reduced folate/methotrexate transport system, were grown in media containing folate levels in the physiological range rather than in standard media supplemented with high folate concentrations. Over a 7-month period folic acid concentrations were gradually lowered from 2 µM to 2 nM without subsequent changes in the transport-defective phenotype. In these cells we observed the up regulation of a membrane-associated folate-binding protein with high affinities for folic acid and reduced folates, but poor affinities for the folate antagonists MTX and 10-ethyl-10-deazaaminopterin. The binding capacity for [³H]folic acid was 12.5 pmol/10⁷ cells, but could be further increased to 30 pmol/10⁷ cells following cell transfer to completely folate-deficient medium for 3 days, except that in the latter situation cell growth stopped. The affinities of the folate-binding protein for 5-methyltetrahydrofolate, folinic acid, and MTX were 0.33, 0.11, and 0.009, respectively, relative to that of folic acid. Growth of CEM/MTX cells was promoted by nanomolar concentrations of either folic acid (median effective concentration, 0.35 nM) or folinic acid (median effective concentration, 0.75 nM), suggesting that the folate-binding protein is not only involved in folate binding, but also in the uptake of folates. The insensitivity of CEM/MTX cells to MTX was correlated with the poor affinity of the folate-binding protein for MTX, compared to folic acid. MTX was only growth inhibitory when added at concentrations at least 30-fold exceeding those of folic acid in the culture medium. On the other hand, CEM/MTX cells grown at 2 µM or 2 nM folic acid were equally sensitive to the lipophilic antifolate trimetrexate.

Despite the low affinity for MTX, the folate-binding protein could be specifically labeled by an N-hydroxysuccinimide ester of [³H]MTX and appeared to have a molecular weight of 44,000 as shown by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. These data suggest that an alternative folate uptake system, a folate-binding protein, can play an important role in transport-related methotrexate resistance. Moreover, since all these effects were observed for CEM/MTX cells grown at folate levels in the physiological range, it is conceivable that this mechanism of methotrexate resistance can also be of significance in leukemic cells in vivo.

¹ This study was supported by Grant UUKC 8516 of the Netherlands Cancer Foundation.

² To whom requests for reprints should be addressed.

Received 8/ 2/88. Revised 1/ 3/89. Accepted 1/11/89.

This article has been cited by other articles:

				J. J. McGuire, W. H. Haile, and C.-C. Yeh 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. Cancer Res., April 1, 2006; 66(7): 3836 - 3844. [Abstract] [Full Text] [PDF]

				D. D. Gibbs, D. S. Theti, N. Wood, M. Green, F. Raynaud, M. Valenti, M. D. Forster, F. Mitchell, V. Bavetsias, E. Henderson, et al. BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to {alpha}-Folate Receptor-Overexpressing Tumors Cancer Res., December 15, 2005; 65(24): 11721 - 11728. [Abstract] [Full Text] [PDF]

				D. S. Theti, V. Bavetsias, L. A. Skelton, J. Titley, D. Gibbs, G. Jansen, and A. L. Jackman Selective Delivery of CB300638, a Cyclopenta[g]quinazoline-based Thymidylate Synthase Inhibitor into Human Tumor Cell Lines Overexpressing the {alpha}-Isoform of the Folate Receptor Cancer Res., July 1, 2003; 63(13): 3612 - 3618. [Abstract] [Full Text] [PDF]

				M. da Costa, S. P. Rothenberg, E. Sadasivan, A. Regec, and L. Qian Folate deficiency reduces the GPI-anchored folate-binding protein in rat renal tubules Am J Physiol Cell Physiol, April 1, 2000; 278(4): C812 - C821. [Abstract] [Full Text] [PDF]

				K. M. Maziarz, H. L. Monaco, F. Shen, and M. Ratnam Complete Mapping of Divergent Amino Acids Responsible for Differential Ligand Binding of Folate Receptors alpha  and beta J. Biol. Chem., April 16, 1999; 274(16): 11086 - 11091. [Abstract] [Full Text] [PDF]

				J. H. Chiao, C.-H. Yang, K. Roy, J. Pain, and F. M. Sirotnak Ligand-directed Immunoaffinity Purification and Properties of the One-carbon, Reduced Folate Transporter J. Biol. Chem., December 15, 1995; 270(50): 29698 - 29704. [Abstract] [Full Text] [PDF]

				M. J. Spinella, K. E. Brigle, E. E. Sierra, and I. D. Goldman Distinguishing between Folate Receptor-alpha-mediated Transport and Reduced Folate Carrier-mediated Transport in L1210 Leukemia Cells J. Biol. Chem., April 7, 1995; 270(14): 7842 - 7849. [Abstract] [Full Text] [PDF]